Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heinz Läubli

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Therapeutische Umschau. Revue Therapeutique|November 16, 2023
[Cellular immunotherapies for malignancies - How do they work and what are the side effects?]Heinz Läubli
Frontiers in Immunology|September 26, 2019
Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and MetastasisHeinz Läubli, Lubor Borsig
Cellular and Molecular Life Sciences : CMLS|September 6, 2019
Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responsesHeinz Läubli, Ajit Varki
Pharmacology|July 30, 2020
Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint InhibitorsDavid König, Heinz Läubli
Carbohydrate Research|April 26, 2024
Regulation of sialic acid metabolism in cancerFilip Filipsky, Heinz Läubli
Expert Opinion on Therapeutic Targets|September 17, 2019
The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunityAnne Bärenwaldt, Heinz Läubli
Expert Opinion on Therapeutic Targets|September 3, 2025
Disrupting Siglec-mediated interactions to develop immunotherapies for cancer treatmentHeinz Läubli, Ajit Varki
Seminars in Cancer Biology|May 11, 2010
Selectins promote tumor metastasisHeinz Läubli, Lubor Borsig
Expert Review of Clinical Immunology|November 10, 2025
Mechanisms of resistance to adoptive cell therapy with tumor-infiltrating lymphocytesDavid König, Heinz Läubli
Swiss Medical Weekly|August 14, 2025
Genetically engineered T cell and tumour-infiltrating lymphocyte therapiesHeinz Läubli, Andreas Holbro
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Therapeutische Umschau. Revue Therapeutique|November 16, 2023
[Cellular immunotherapies for malignancies - How do they work and what are the side effects?]Heinz Läubli
Frontiers in Immunology|September 26, 2019
Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and MetastasisHeinz Läubli, Lubor Borsig
Cellular and Molecular Life Sciences : CMLS|September 6, 2019
Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responsesHeinz Läubli, Ajit Varki
Pharmacology|July 30, 2020
Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint InhibitorsDavid König, Heinz Läubli
Carbohydrate Research|April 26, 2024
Regulation of sialic acid metabolism in cancerFilip Filipsky, Heinz Läubli
Expert Opinion on Therapeutic Targets|September 17, 2019
The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunityAnne Bärenwaldt, Heinz Läubli
Expert Opinion on Therapeutic Targets|September 3, 2025
Disrupting Siglec-mediated interactions to develop immunotherapies for cancer treatmentHeinz Läubli, Ajit Varki
Seminars in Cancer Biology|May 11, 2010
Selectins promote tumor metastasisHeinz Läubli, Lubor Borsig
Expert Review of Clinical Immunology|November 10, 2025
Mechanisms of resistance to adoptive cell therapy with tumor-infiltrating lymphocytesDavid König, Heinz Läubli
Swiss Medical Weekly|August 14, 2025
Genetically engineered T cell and tumour-infiltrating lymphocyte therapiesHeinz Läubli, Andreas Holbro
Pageof 11